Mepolizumab decreases urinary excretion of LTE4 in severe asthma Source: Virtual Congress 2020 – New insight into the pathogenesis of chronic lung diseases: asthma, COPD and others Year: 2020
Thromboxane B2 (TXB2) urine levels during long term treatment with montelukast (M) in asthmatic subjects Source: Eur Respir J 2001; 18: Suppl. 33, 353s Year: 2001
The influence of antileukotriene therapy with montelukast (M) on thromboxane B2 /leukotriene E4 (TXB2 /LTE4 ) ratio in the urine of asthmatic subjects and other inflammatory markers Source: Eur Respir J 2003; 22: Suppl. 45, 102s Year: 2003
Evaluation of prostaglandin-E-main urinary metabolite (PGE-MUM) in idiopathic pulmonary fibrosis (IPF) Source: Eur Respir J 2007; 30: Suppl. 51, 573s Year: 2007
Nasal polyps support a higher LTE4 urinary excretion in aspirin-induced asthma (AIA) Source: Eur Respir J 2004; 24: Suppl. 48, 509s Year: 2004
The effect of tiotropium (TIO) on levels of desmosine and isodesmosine (D/I) in urine, plasma and sputum in COPD Source: Annual Congress 2007 - Mechanisms and new treatments of COPD Year: 2007
Urinary LTE4 is increased proportionally to asthma severity in steroid-treated patients vs healthy controls Source: Eur Respir J 2004; 24: Suppl. 48, 259s Year: 2004
Urinary cysteinyl leukotriene levels in acute asthma Source: Eur Respir J 2003; 22: Suppl. 45, 179s Year: 2003
Urinary uric acid excretion and overnight change in the urinary uric acid: creatinin ratio as a marker of tissue hypoxia in patients with COPD and OSA Source: Eur Respir J 2006; 28: Suppl. 50, 408s Year: 2006
Aspirin significantly decreases urinary leukotriene E4 concentration in aspirin-tolerant asthma patients who show hyperleukotrienuria in stable condition Source: Annual Congress 2007 - New mechanisms in the pathogenesis of asthma and allergy Year: 2007
Urinary levels of LTE4 in infants with RSV positive bronchiolitis Source: Eur Respir J 2003; 22: Suppl. 45, 211s Year: 2003
Plasma 6-ketoPGF1α, a stable metabolite of prostaglandin I2 shows a marked decrease in patients with COPD Source: Eur Respir J 2006; 28: Suppl. 50, 651s Year: 2006
LATE-BREAKING ABSTRACT: The applicability of urinary leukotriene E4 (uLTE4) measurement as a non-invasive method for diagnosis of aspirin exacerbated respiratory disease (AERD). Source: International Congress 2014 – Asthma or COPD: comorbid condition or a poorly understood single disease? Year: 2014
Measurement of leukotrienes urinary excretion in patients with bronchial asthma Source: Eur Respir J 2003; 22: Suppl. 45, 371s Year: 2003
Plasma concentrations of four corticosteroids following inhalation Source: Eur Respir J 2005; 26: Suppl. 49, 215s Year: 2005
Anti-inflammatory effect of montelukast (ML) and inhaled steroids (ICS) on clinical parameters and serum levels of NO in asthmatic children Source: Eur Respir J 2003; 22: Suppl. 45, 132s Year: 2003
COPD: Inhaled corticosteroid (ICS) and long-acting beta2-agonist (LABA) combination and oxygen saturation (OS) in patients (pts) with different plasma surfactant protein D (SP-D) level Source: International Congress 2015 – COPD: notable points Year: 2015
CRP and LTE4 in COPD Source: Annual Congress 2008 - Structural remodelling in COPD Year: 2008
Urinary cotinine level in asthmatic children Source: Annual Congress 2008 - Early life risk factors for childhood asthma: evidence from birth cohort studies II Year: 2008
Measurement of tumor necrosis factor (TNF)α, leukotriene B4 (LTB4), and interleukin 8 (IL8) in the exhaled breath condensate (EBC) in patients with acute exacerbations of chronic obstructive pulmonary disease (AECOPD) Source: Eur Respir J 2007; 30: Suppl. 51, 584s Year: 2007